Jean-Louis Alberini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jean-Louis Alberini has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Benoit Presles
CNRS, ICMUB UMR 6302, Université Bourgogne Europe, 21000, Dijon, France
3 shared publications - Jean-Marc Vrigneaud
Centre Georges-François Leclerc, service de médecine nucléaire, CNRS, ICMUB UMR 6302, Université Bourgogne Europe, 21000, Dijon, France.
3 shared publications Romain Popoff
Centre Georges-François Leclerc, service de médecine nucléaire, CNRS, ICMUB UMR 6302, Université Bourgogne Europe, 21000, Dijon, France
3 shared publicationsAlexandre Cochet
Laboratoire ICMUB, CNRS UMR 6302, Université de Bourgogne, Dijon, France
2 shared publicationsBernard Bonnotte
Department of Internal Medicine and Clinical Immunology, Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases (MAIS), Dijon Bourgogne University Hospital, Dijon, France; INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Bourgogne Franche-Comté University, Dijon, France
2 shared publications- Félix Quinton
Université Bourgogne Europe, CNRS, ICMUB UMR 6302, Dijon, France
2 shared publications
Latest Publications
- Open Access
- 25 June 2026
- Published by Springer Nature in EJNMMI Physics
- Vol. 13 (1)
Optimising $^{90}Y$ PET imaging for dosimetry in SIRT: insights from phantom and simulation studies on the Discovery MI scannerThe aim of this study was to optimise the acquisition and reconstruction parameters for [Formula: see text] imaging on a digital PET scanner (Discovery MI 4-ring) under high (3 GBq), intermediate (1 GBq), and low (200 MBq) activity conditions. First, quantitative linearity was evaluated. Then, NEMA IEC body phantom acquisitions were reconstructed using various scan durations and Q.Clear reconstruction parameters. Next, optimal protocols were identified by minimising the discrepancies between absorbed dose maps derived from images (using the Local Deposition Model (LDM)) and those obtained from Monte Carlo (MC) simulations. The images reconstructed with these optimal protocols were then used to evaluate effective spatial resolution and to compare the accuracy of LDM with that of the Dose Voxel Kernel (DVK) approach. Quantitative linearity analysis revealed an underestimation of phantom activity at high activity (up to - 15.7% at 3.6 GBq) and an overestimation at lower levels (up to 52.1% at 208 MBq). At high activity, the most accurate results were produced by 15- and 20-minute acquisitions with intermediate beta values (2000-5000). In contrast, intermediate and low activity levels required longer acquisition times and higher beta values (> 6000). Effective spatial resolution ranged from 7 mm at high activity to 24.9 mm at low activity. In terms of absorbed dose accuracy, the mean absorbed dose was underestimated in all spheres of the phantom. However, the error in the mean absorbed dose could be kept within 10% in the background by applying non-linearity corrections. Using MC as reference, LDM achieved greater accuracy in terms of mean absorbed dose and Dose Volume Histogram (DVH) agreement in the spheres, while DVK performed better in the background. This study enabled the optimisation of scan duration and beta parameter values for Q.Clear reconstructions for dosimetric purposes. Although accurate dosimetry remains challenging in [Formula: see text] PET imaging due to quantitative nonlinearity and limited spatial resolution, an error of less than 10% on the mean absorbed dose can be achieved in large structures if model-specific nonlinearities are corrected for.
- 25 June 2026
- Published by Springer Nature in EJNMMI Physics
- Vol. 13 (1)
Open AccessOptimising $^{90}Y$ PET imaging for dosimetry in SIRT: insights from phantom and simulation studies on the Discovery MI scannerThe aim of this study was to optimise the acquisition and reconstruction parameters for [Formula: see text] imaging on a digital PET scanner (Discovery MI 4-ring) under high (3 GBq), intermediate (1 GBq), and low (200 MBq) activity conditions. First, quantitative linearity was evaluated. Then, NEMA IEC body phantom acquisitions were reconstructed using various scan durations and Q.Clear reconstruction parameters. Next, optimal protocols were identified by minimising the discrepancies between absorbed dose maps derived from images (using the Local Deposition Model (LDM)) and those obtained from Monte Carlo (MC) simulations. The images reconstructed with these optimal protocols were then used to evaluate effective spatial resolution and to compare the accuracy of LDM with that of the Dose Voxel Kernel (DVK) approach. Quantitative linearity analysis revealed an underestimation of phantom activity at high activity (up to - 15.7% at 3.6 GBq) and an overestimation at lower levels (up to 52.1% at 208 MBq). At high activity, the most accurate results were produced by 15- and 20-minute acquisitions with intermediate beta values (2000-5000). In contrast, intermediate and low activity levels required longer acquisition times and higher beta values (> 6000). Effective spatial resolution ranged from 7 mm at high activity to 24.9 mm at low activity. In terms of absorbed dose accuracy, the mean absorbed dose was underestimated in all spheres of the phantom. However, the error in the mean absorbed dose could be kept within 10% in the background by applying non-linearity corrections. Using MC as reference, LDM achieved greater accuracy in terms of mean absorbed dose and Dose Volume Histogram (DVH) agreement in the spheres, while DVK performed better in the background. This study enabled the optimisation of scan duration and beta parameter values for Q.Clear reconstructions for dosimetric purposes. Although accurate dosimetry remains challenging in [Formula: see text] PET imaging due to quantitative nonlinearity and limited spatial resolution, an error of less than 10% on the mean absorbed dose can be achieved in large structures if model-specific nonlinearities are corrected for.
- 27 May 2026
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 56 (4) , 736-747
PET imaging of large-vessel vasculitis: advancements and future trends
- 27 May 2026
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 56 (4) , 736-747
PET imaging of large-vessel vasculitis: advancements and future trends
- Open Access
- 17 May 2026
- Published by Springer Nature in EJNMMI Physics
- Vol. 13 (1)
Assessing the suitability of automated registration and segmentation for dosimetry calculations in SIRT treatment planning
Background: Selective internal radiation therapy (SIRT) increasingly relies on accurate magnetic resonance imaging (MRI) to computed tomography (CT) registration and accurate liver and tumour segmentation, for effective pre-treatment planning. This study evaluates the impact of automatic registration and segmentation techniques on dosimetry calculations for SIRT treatment planning. It compares semi-automatic and automatic registration, as well as manual and automatic deep learning-based segmentation. Methods: Pre-treatment data from 90 patients with hepatocellular carcinoma were analysed. The dataset consisted of contrast-enhanced T1-weighted MRI scans with manually delineated liver and tumour volumes of interest (VOIs), as well as single-photon emission computed tomography (SPECT)/CT scans with manually or semi-automatically delineated liver VOI. The clinical routine pipeline, which involves semi-automatic registration and manual/semi-automatic segmentation, was used as the baseline pipeline and compared to experimental pipelines that use intensity-based deformable automatic registration or deep learning-based automatic segmentation. Dosimetric accuracy was assessed via metrics such as the mean absorbed dose, the minimum dose received by 70% of the volume (D70), and inverted cumulative dose-volume histograms. Results: Semi-automatic and automatic MRI to CT liver registration achieved comparable Dice scores of 92%. However, tumour registration varied significantly between registration methods yielding average Dice scores of 79%. Multimodal tumour segmentation approaches outperformed monomodal ones, achieving average Dice scores of 66.6 versus 62.5%. Using the baseline pipeline, the average tumour absorbed dose per patient was 115.6 Gy. Using the fully automatic approach, tumour absorbed doses differed from baseline values by an average of 6.6 Gy. Differences ranged from 0.3 Gy in the best case to 202.8 Gy when the automatic tumour segmentation markedly deviated from the manual delineation. Finally, it was found that a Dice score of at least 80% was required to avoid statistically significant differences in absorbed dose estimates between the clinical and automatic approaches. Conclusion: Semi-automatic and automatic registration show equivalent performance, allowing for complete automation. Automatic segmentation demonstrates promising results, with approximately 40% of patients achieving tumour Dice scores above the 80% threshold. 30% of cases show intermediate performance (60–80% tumour Dice scores), while the remaining 30% are still challenging. Further refinement of segmentation methods is required to enhance dosimetric accuracy.
- 17 May 2026
- Published by Springer Nature in EJNMMI Physics
- Vol. 13 (1)
Open AccessAssessing the suitability of automated registration and segmentation for dosimetry calculations in SIRT treatment planning
Background: Selective internal radiation therapy (SIRT) increasingly relies on accurate magnetic resonance imaging (MRI) to computed tomography (CT) registration and accurate liver and tumour segmentation, for effective pre-treatment planning. This study evaluates the impact of automatic registration and segmentation techniques on dosimetry calculations for SIRT treatment planning. It compares semi-automatic and automatic registration, as well as manual and automatic deep learning-based segmentation. Methods: Pre-treatment data from 90 patients with hepatocellular carcinoma were analysed. The dataset consisted of contrast-enhanced T1-weighted MRI scans with manually delineated liver and tumour volumes of interest (VOIs), as well as single-photon emission computed tomography (SPECT)/CT scans with manually or semi-automatically delineated liver VOI. The clinical routine pipeline, which involves semi-automatic registration and manual/semi-automatic segmentation, was used as the baseline pipeline and compared to experimental pipelines that use intensity-based deformable automatic registration or deep learning-based automatic segmentation. Dosimetric accuracy was assessed via metrics such as the mean absorbed dose, the minimum dose received by 70% of the volume (D70), and inverted cumulative dose-volume histograms. Results: Semi-automatic and automatic MRI to CT liver registration achieved comparable Dice scores of 92%. However, tumour registration varied significantly between registration methods yielding average Dice scores of 79%. Multimodal tumour segmentation approaches outperformed monomodal ones, achieving average Dice scores of 66.6 versus 62.5%. Using the baseline pipeline, the average tumour absorbed dose per patient was 115.6 Gy. Using the fully automatic approach, tumour absorbed doses differed from baseline values by an average of 6.6 Gy. Differences ranged from 0.3 Gy in the best case to 202.8 Gy when the automatic tumour segmentation markedly deviated from the manual delineation. Finally, it was found that a Dice score of at least 80% was required to avoid statistically significant differences in absorbed dose estimates between the clinical and automatic approaches. Conclusion: Semi-automatic and automatic registration show equivalent performance, allowing for complete automation. Automatic segmentation demonstrates promising results, with approximately 40% of patients achieving tumour Dice scores above the 80% threshold. 30% of cases show intermediate performance (60–80% tumour Dice scores), while the remaining 30% are still challenging. Further refinement of segmentation methods is required to enhance dosimetric accuracy.
- 2 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Imagerie moléculaire de biomarqueurs dans le cancer mammaire
L’imagerie moléculaire avec des biomarqueurs radiomarqués par des émetteurs de positons est couramment utilisée dans les cancers mammaires infiltrants pour la stadification initiale ou en cas de récidive, et également pour l’évaluation de la réponse tumorale en situation néoadjuvante et métastatique. Après quelques notions générales sur les cancers mammaires et le rôle alloué à l’imagerie moléculaire, les résultats des travaux axés sur l’imagerie moléculaire des cancers mammaires que j’ai encadrés et auxquels j’ai contribués au sein de l’équipe de Médecine Nucléaire de l’Institut Curie - Saint-Cloud sont présentés. Ces études ont évalué la valeur de la Tomographie par Emission de Positons au FluoroDesoxyGlucose (TEP-FDG) en cas de suspicion biologique de récidive, ou pour la stadification initiale et l’évaluation de la réponse tumorale à la Chimiothérapie NéoAdjuvante (CNA) des cancers mammaires inflammatoires. Notre équipe a également étudié la valeur pronostique de la réponse tumorale à l’hormonothérapie par la TEP-FDG, en situation métastatique. La problématique de l’évaluation précoce de la réponse tumorale à la CNA par l'imagerie moléculaire m’a amené à étudier un modèle murin transgénique de cancer mammaire avec d’autres biomarqueurs que le FDG, à savoir la FLuoroThymidine (FLT) et le pertechnetate. Des outils de quantification de la charge tumorale ont pu être développés et ont permis d’évaluer la réponse tumorale à des drogues cytotoxiques lors d’un suivi longitudinal, mais ce travail s’est heurté aux limites de l’imagerie préclinique. Les résultats des études cliniques sur l’évaluation précoce de la réponse tumorale à la CNA sont ensuite exposés, avec le FDG comme biomarqueur en insistant sur l’influence du phénotype moléculaire sur les paramètres définissant une réponse métabolique. L’état des connaissances et les perspectives avec d’autres biomarqueurs que le FDG, à savoir la FLT et le FluoroEStradiol (FES), pour étudier respectivement la prolifération cellulaire tumorale et la présence et la fonctionnalité des récepteurs aux estrogènes, puis l’imagerie en développement de l’Human Epidermal Growth Factor Receptor-2 (HER2), destinés à la fois à la sélection de patients candidats à des thérapies innovantes et à la prédiction et l’évaluation de la réponse tumorale aux thérapies sont discutées.
- 2 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Imagerie moléculaire de biomarqueurs dans le cancer mammaire
L’imagerie moléculaire avec des biomarqueurs radiomarqués par des émetteurs de positons est couramment utilisée dans les cancers mammaires infiltrants pour la stadification initiale ou en cas de récidive, et également pour l’évaluation de la réponse tumorale en situation néoadjuvante et métastatique. Après quelques notions générales sur les cancers mammaires et le rôle alloué à l’imagerie moléculaire, les résultats des travaux axés sur l’imagerie moléculaire des cancers mammaires que j’ai encadrés et auxquels j’ai contribués au sein de l’équipe de Médecine Nucléaire de l’Institut Curie - Saint-Cloud sont présentés. Ces études ont évalué la valeur de la Tomographie par Emission de Positons au FluoroDesoxyGlucose (TEP-FDG) en cas de suspicion biologique de récidive, ou pour la stadification initiale et l’évaluation de la réponse tumorale à la Chimiothérapie NéoAdjuvante (CNA) des cancers mammaires inflammatoires. Notre équipe a également étudié la valeur pronostique de la réponse tumorale à l’hormonothérapie par la TEP-FDG, en situation métastatique. La problématique de l’évaluation précoce de la réponse tumorale à la CNA par l'imagerie moléculaire m’a amené à étudier un modèle murin transgénique de cancer mammaire avec d’autres biomarqueurs que le FDG, à savoir la FLuoroThymidine (FLT) et le pertechnetate. Des outils de quantification de la charge tumorale ont pu être développés et ont permis d’évaluer la réponse tumorale à des drogues cytotoxiques lors d’un suivi longitudinal, mais ce travail s’est heurté aux limites de l’imagerie préclinique. Les résultats des études cliniques sur l’évaluation précoce de la réponse tumorale à la CNA sont ensuite exposés, avec le FDG comme biomarqueur en insistant sur l’influence du phénotype moléculaire sur les paramètres définissant une réponse métabolique. L’état des connaissances et les perspectives avec d’autres biomarqueurs que le FDG, à savoir la FLT et le FluoroEStradiol (FES), pour étudier respectivement la prolifération cellulaire tumorale et la présence et la fonctionnalité des récepteurs aux estrogènes, puis l’imagerie en développement de l’Human Epidermal Growth Factor Receptor-2 (HER2), destinés à la fois à la sélection de patients candidats à des thérapies innovantes et à la prédiction et l’évaluation de la réponse tumorale aux thérapies sont discutées.
- Open Access
- 31 December 2025
- Published by Elsevier in Artificial Intelligence in Medicine
- Vol. 173, 103348
Tackling data scarcity: Synthetic tumour and mask generation to improve image segmentation
- 31 December 2025
- Published by Elsevier in Artificial Intelligence in Medicine
- Vol. 173, 103348
Open AccessTackling data scarcity: Synthetic tumour and mask generation to improve image segmentation
- Open Access
- 15 April 2024
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 126, 69-76
Prognostic value of 18 FDG-PET at diagnosis and follow-up in giant cell arteritis: An observational restrospective study
- 15 April 2024
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 126, 69-76
Open AccessPrognostic value of 18 FDG-PET at diagnosis and follow-up in giant cell arteritis: An observational restrospective study
- Open Access
- 24 October 2022
- Published by Springer Nature in Research Square
Diagnostic performance of digital PET with a dedicated head and neck protocol for the assessment of cranial arteries inflammation in Giant Cell Arteritis
Introduction Giant cell arteritis (GCA) is a frequent granulomatous vasculitis. In the diagnosis of large vessel GCA, FDG-PET/CT imaging has been recommended and its use has steadily increased. The objective of this prospective study was to evaluate the diagnostic performance of digital FDG-PET imaging with a head and neck dedicated protocol, especially to detect cranial arteries involvement, using different visual grading scores, and to assess the inter-reader agreement. Material and Methods FDG-PET/CT scans with a 10-min acquisition time on the head and neck were performed in patients suspected of having recent GCA. A score including 20 segments due to the inclusion of cranial segments and a score established only for the cranial segments were compared to the Total Vascular Score (TVS) established on 7 arterial segments. These scores were assessed by two nuclear medicine physicians on a blinded manner and, in case of disagreement, a consensus was established with a third nuclear medicine physician. Results GCA diagnosis was retained for 15 of the 52 patients included. Sensitivity and specificity of the 20-segment or the cranial scores were higher than those of TVS (sensitivity and specificity of 80% of 97% for both scores vs 73% and 89% for TVS, respectively). The inter-reader agreement was substantial in the 20-segment score (weighted kappa = 0.68) but better in the cranial segments than other segments. Conclusion This study shows the usefulness of grading scores able to highlight involvement of cranial arteries in GCA with a better inter-reader agreement in cranial segments than other segments.
- 24 October 2022
- Published by Springer Nature in Research Square
Open AccessDiagnostic performance of digital PET with a dedicated head and neck protocol for the assessment of cranial arteries inflammation in Giant Cell Arteritis
Introduction Giant cell arteritis (GCA) is a frequent granulomatous vasculitis. In the diagnosis of large vessel GCA, FDG-PET/CT imaging has been recommended and its use has steadily increased. The objective of this prospective study was to evaluate the diagnostic performance of digital FDG-PET imaging with a head and neck dedicated protocol, especially to detect cranial arteries involvement, using different visual grading scores, and to assess the inter-reader agreement. Material and Methods FDG-PET/CT scans with a 10-min acquisition time on the head and neck were performed in patients suspected of having recent GCA. A score including 20 segments due to the inclusion of cranial segments and a score established only for the cranial segments were compared to the Total Vascular Score (TVS) established on 7 arterial segments. These scores were assessed by two nuclear medicine physicians on a blinded manner and, in case of disagreement, a consensus was established with a third nuclear medicine physician. Results GCA diagnosis was retained for 15 of the 52 patients included. Sensitivity and specificity of the 20-segment or the cranial scores were higher than those of TVS (sensitivity and specificity of 80% of 97% for both scores vs 73% and 89% for TVS, respectively). The inter-reader agreement was substantial in the 20-segment score (weighted kappa = 0.68) but better in the cranial segments than other segments. Conclusion This study shows the usefulness of grading scores able to highlight involvement of cranial arteries in GCA with a better inter-reader agreement in cranial segments than other segments.
- Open Access
- 28 January 2020
- Published by Springer Nature in Cancer Imaging
- Vol. 20 (1) , 1-9
Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response
Background: Neoadjuvant endocrine therapy (NET) has shown efficacy in terms of clinical response and surgical outcome in postmenopausal patients with estrogen receptor-positive / HER2-negative breast cancer (ER+/HER2- BC) but monitoring of tumor response is challenging. The aim of the present study was to investigate the value of an early metabolic response compared to morphological and pathological responses in this population. Methods: This was an ancillary study of CARMINA 02, a phase II clinical trial evaluating side-by-side the efficacy of 4 to 6 months of anastrozole or fulvestrant. Positron Emission Tomography/Computed Tomography using 2-deoxy-2-[18F]fluoro-D-glucose (FDG-PET/CT) scans were performed at baseline (M0), early after 1 month of treatment (M1) and pre-operatively in 11 patients (74.2 yo ± 3.6). Patients were classified as early “metabolic responders” (mR) when the decrease of SUVmax was higher than 40%, and “metabolic non-responders” (mNR) otherwise. Early metabolic response was compared to morphological response (palpation, US and MRI), variation of Ki-67 index, pathological response according to the Sataloff classification and also to Preoperative Endocrine Prognostic Index (PEPI) score. It was also correlated with overall survival (OS) and recurrence-free survival (RFS). Results: Tumor size measured on US and on MRI was smaller in mR than mNR, with the highest statistically significant difference at M1 (p = 0.01 and 7.1 × 10− 5, respectively). No statistically significant difference in the variation of tumor size between M0 and M1 assessed on US or MRI was observed between mR and mNR. mR had a better clinical response: no progressive disease in mR vs 2 in mNR and 2 partial response in mR vs 1 partial response in mNR. One patient with a pre-operative complete metabolic response had the best pathological response. Pathological response did not show any statistically significant difference between mR and mNR. mR had better OS and RFS (Kaplan-Meier p = 0.08 and 0.06, respectively). All cancer-related events occurred in mNR: 3 patients died, 2 of them from progressive disease. Conclusions: FDG-PET/CT imaging could become a “surrogate marker” to monitor tumor response, especially as NET is a valuable treatment option in postmenopausal women with ER+/HER2- BC.
- 28 January 2020
- Published by Springer Nature in Cancer Imaging
- Vol. 20 (1) , 1-9
Open AccessEarly metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response
Background: Neoadjuvant endocrine therapy (NET) has shown efficacy in terms of clinical response and surgical outcome in postmenopausal patients with estrogen receptor-positive / HER2-negative breast cancer (ER+/HER2- BC) but monitoring of tumor response is challenging. The aim of the present study was to investigate the value of an early metabolic response compared to morphological and pathological responses in this population. Methods: This was an ancillary study of CARMINA 02, a phase II clinical trial evaluating side-by-side the efficacy of 4 to 6 months of anastrozole or fulvestrant. Positron Emission Tomography/Computed Tomography using 2-deoxy-2-[18F]fluoro-D-glucose (FDG-PET/CT) scans were performed at baseline (M0), early after 1 month of treatment (M1) and pre-operatively in 11 patients (74.2 yo ± 3.6). Patients were classified as early “metabolic responders” (mR) when the decrease of SUVmax was higher than 40%, and “metabolic non-responders” (mNR) otherwise. Early metabolic response was compared to morphological response (palpation, US and MRI), variation of Ki-67 index, pathological response according to the Sataloff classification and also to Preoperative Endocrine Prognostic Index (PEPI) score. It was also correlated with overall survival (OS) and recurrence-free survival (RFS). Results: Tumor size measured on US and on MRI was smaller in mR than mNR, with the highest statistically significant difference at M1 (p = 0.01 and 7.1 × 10− 5, respectively). No statistically significant difference in the variation of tumor size between M0 and M1 assessed on US or MRI was observed between mR and mNR. mR had a better clinical response: no progressive disease in mR vs 2 in mNR and 2 partial response in mR vs 1 partial response in mNR. One patient with a pre-operative complete metabolic response had the best pathological response. Pathological response did not show any statistically significant difference between mR and mNR. mR had better OS and RFS (Kaplan-Meier p = 0.08 and 0.06, respectively). All cancer-related events occurred in mNR: 3 patients died, 2 of them from progressive disease. Conclusions: FDG-PET/CT imaging could become a “surrogate marker” to monitor tumor response, especially as NET is a valuable treatment option in postmenopausal women with ER+/HER2- BC.
- 1 April 1999
- Published by Lavoisier in Acta Endoscopica
- Vol. 29 (2) , 129-138
Intérêt de la tomographie à émission de positrons dans l’évaluation des tumeurs gastro-intestinales
La TEP au 18FDG présente de nombreuses indications dans l’évaluation des tumeurs digestives. Son rôle principal concerne le bilan d’extension des récidives tumorales démontrées ou suspectées mais des indications plus ponctuelles concernent également le diagnostic différentiel des masses pancréatiques et le bilan initial du cancer de l’œsophage. Le principal avantage de la TEP résulte de la nature métabolique du signal, indépendant et complémentaire des modifications anatomiques visibles en imagerie classique. Un autre avantage est lié à l’examen du corps entier aujourd’hui pratiqué systématiquement. La TEP trouve dès lors sa place en première ligne dans ses différentes indications. PET with 18-FDG has numerous indications in the evaluation of patients with gastrointestinal carcinoma. Its principal indications are the staging of suspected or demonstrated recurrent disease and to assess the operability of lesion. Validated indications also concern the differential diagnosis of pancreatic masses and the initial staging of oesophageal cancer. The metabolic signal of PET constitutes its main advantage. It is independent but complementary to the anatomical changes assessed by structural imaging. Another advantage is related to imaging of the whole-body is now routinely performed. PET can thus be a one step examination in the staging of digestive cancers and is best used early in the staging process.
- 1 April 1999
- Published by Lavoisier in Acta Endoscopica
- Vol. 29 (2) , 129-138
Intérêt de la tomographie à émission de positrons dans l’évaluation des tumeurs gastro-intestinales
La TEP au 18FDG présente de nombreuses indications dans l’évaluation des tumeurs digestives. Son rôle principal concerne le bilan d’extension des récidives tumorales démontrées ou suspectées mais des indications plus ponctuelles concernent également le diagnostic différentiel des masses pancréatiques et le bilan initial du cancer de l’œsophage. Le principal avantage de la TEP résulte de la nature métabolique du signal, indépendant et complémentaire des modifications anatomiques visibles en imagerie classique. Un autre avantage est lié à l’examen du corps entier aujourd’hui pratiqué systématiquement. La TEP trouve dès lors sa place en première ligne dans ses différentes indications. PET with 18-FDG has numerous indications in the evaluation of patients with gastrointestinal carcinoma. Its principal indications are the staging of suspected or demonstrated recurrent disease and to assess the operability of lesion. Validated indications also concern the differential diagnosis of pancreatic masses and the initial staging of oesophageal cancer. The metabolic signal of PET constitutes its main advantage. It is independent but complementary to the anatomical changes assessed by structural imaging. Another advantage is related to imaging of the whole-body is now routinely performed. PET can thus be a one step examination in the staging of digestive cancers and is best used early in the staging process.